Profiles of Plasminogen Activator Inhibitor-1 Levels in Healthcare Workers with Latent Tuberculosis and Non-Latent Tuberculosis Infections (Healthy Control)

Author:

Tonapa Sanrio Neuro,Ahmad Nur,Saleh Sahyuddin,Bakri Syakib,Minhajat Rahmawati,Akil Fardah,Seweng Arifin

Abstract

Background: Mycobacterium tuberculosis infection causes the release of proinflammatory cytokines; interleukin IL-1, IL-6, and IL-8, as well as tumor necrosis factor (TNF-α), affecting hemostasis, namely an increase in procoagulation activity, a decrease in anticoagulant factors, and suppression of the fibrinolytic system that causes hypercoagulable states. Methods: This is a cross-sectional study that involves 80 healthcare workers. The study was conducted in two academic medical centers that were part of the healthcare system of Makassar city, South Sulawesi province, Indonesia, from September to October 2021. PAI-1 levels were measured using the enzyme-linked immunosorbent assay technique. The statistical test results were significant if the p values were <0.05. Results: Although there was no statistically significant difference (P > 0.05) in PAI-1 levels, PAI-1 level among participants in the LTBI group was found to be lower (4.9 ng/mL) than in the healthy control group (6.0 ng/mL). In addition, participants in the LTBI group with a history of being infected (9.6 ng/mL) with the COVID-19 had higher PAI-1 levels than those who had never been infected (2.3 ng/mL), which is statistically significant (P = 0.004). Although there was no statistically significant difference (P > 0.05) in PAI-1 levels among participants in the healthy control group, those with a history of being infected (6.7 ng/mL) demonstrated higher PAI-1 levels than those who had never been infected (4.8 ng/mL). Conclusions: PAI-1 levels were lower in LTBI participants than in healthy control participants, which potentially is due to more participants in the healthy control group having a history of COVID-19 infection.

Publisher

Scientific Foundation SPIROSKI

Subject

General Medicine

Reference19 articles.

1. Sotgiu G, Centis R, D’ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspect Med. 2015;5(5):a017822.

2. World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization; 2018. Available from: https://www.who.int [Last accessed on 2022 Apr 20].

3. Kemenkes RI. [Infodatin: Found tuberculosis and treat until recovered]. Infodatin: Tuberkulosis Temukan Obati Sampai Sembuh. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan RI; 2018. Available from: https://pusdatin.kemkes.go.id [Last accessed on 2022 Feb 22].

4. Jeong YJ, Lee KS, Yim JJ. The diagnosis of pulmonary tuberculosis: A Korean perspective. Prec Future Med. 2017;1(2):77-87.

5. Hamidah RW, Made MN, Soedarsono S. Risk factors of latent tuberculosis infection in healthcare workers at hospitals in jember city indonesia. Afr J Infect Dis. 2021;15(1):34-40. https://doi.org/10.21010/ajid.v15i1.4 PMid:33884356

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3